GD2-CART01
Phase 2Cell therapy
GD2-CART01 is one of 78 biologic programs targeting Pediatric. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
77
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
88 competitors in Neuroblastoma
#DrugCompanyPhaseTrials
1Cytoxan
BBaxter Healthcare Corporation
Phase 3
Vepesid
AAvyxa
Phase 3
Paraplatin
AAvyxa
Phase 3
Leukine
SanofiPhase 3
Camptosar
PfizerPhase 3
Tepadina
Jazz PharmaceuticalsPhase 3
Alkeran
AApotex Inc.
Phase 3
Accutane
CConrado Roberto Hoffmann Filho
Phase 3
Adriamycin
PfizerPhase 3
Oncovin
Eli LillyPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Neuroblastoma1 trial
Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors
Active, not recruiting·—·Phase 1/2·NCT03373097·42 enrolled
Pediatric1 trial
GD2-CAR T Cells for Pediatric Brain Tumours
Recruiting·—·Phase 1·NCT05298995·54 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GD2-CART01. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details